ImpediMed Limited IPDQF

Company Overview

ImpediMed Limited is an Australian medical technology company focused on the development and commercialization of bioimpedance spectroscopy (BIS) technologies used for fluid status assessment and chronic disease monitoring. The company primarily operates in the healthcare technology and digital health sectors, with a strategic focus on oncology-related lymphatic complications, heart failure monitoring, and fluid management applications. Its flagship platform, SOZO Digital Health Platform, is designed to support early detection and management of lymphedema, particularly in breast cancer patients, through non-invasive measurement technology.

The company’s primary revenue drivers are device sales, software subscriptions, recurring patient monitoring services, and related clinical support offerings tied to the SOZO platform. ImpediMed serves hospitals, cancer centers, oncology practices, and healthcare systems, particularly in the United States and Australia. A key strategic advantage has been its position in evidence-based BIS monitoring, supported by clinical studies and guideline inclusion for lymphedema surveillance. Founded in Australia, the company evolved from a medical device developer into a digital health and patient monitoring business with a recurring-revenue model centered on oncology care pathways.